Objective
=========

To investigate the effects of high dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) on the synovial infiltrate in rheumatoid arthritis.

Methods
=======

8 patients with erosive, refractory, progressively rheumatoid arthritis, were treated with HDC (cyclophosphamide 200 mg/kg) and CD34 enriched selected ASCT. Biopsies of synovial tissue from a clinically involved knee were obtained by arthroscopy before and three months after HDC and ASCT. Immunohistochemistry was performed and blindly scored on a five point scale (0-4) using MoAbs specific for the following markers: CD3, CD4, CD8, CD25, CD27, CD45RA, CD45RO, CD45RB, CD19, CD20, CD22, CD38, CD5, CD68, HLA-DR, CD62L, CD62E, CD56 and CD55.

Results
=======

There were no statistical significant differences (Wilcoxon\'s signed rank test) when the results before and after transplantation were compared. However when patients were divided in clinical responders (ACR \> 50%, *n* = 5) and non-responders (ACR \< 20%, *n* = 3) statistically significant differences with respect to several T-cell markers were found (Table).

           Responders   Non-responders                           
  -------- ------------ ---------------- ----------- ----------- ---------
           Before       After            Before      After       *P*^\*^
                                                                 
  CD 3     2.8 ± 0.5    1.3 ± 2.3        1.0 ± 1.4   1.7 ± 2.1   0.06
  CD27     3.0 ± 0.8    0.3 ± 0.6        1.0 ± 0.8   1.7 ± 2.1   0.05
  CD45RA   2.3 ± 0.9    0.7 ± 1.2        0.5 ± 1     1.6 ± 2.1   0.03
  CD45RO   3.4 ± 0.5    0.7 ± 1.2        1.8 ± 1.6   2.0 ± 2     0.04
  CD45RB   3.2 ± 0.8    1.0 ± 1.7        2.0 ± 1.6   2.0 ± 2.0   0.05

Mean Histological Score ± STDEV. ^\*^ Mann-Whitney U test. Clinical and immunohistochemical responses were predicted by CD27 (*P* = 0.016), CD45RO (*P* = 0.003) and CD45RB (*P* = 0.047) infiltration before treatment.

Conclusions
===========

There was a statistically significant difference (*P* \< 0.05) between clinical responders and non-responders with respect to a decrease in infiltration of CD45RA+ and CD45RO+ cells after HDC and ASCT. CD27, CD45RO and CD45RB appear to be useful markers to predict clinical response.
